Q1 Earnings Estimate for Lantheus Issued By Leerink Partnrs

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for Lantheus in a note issued to investors on Tuesday, February 18th. Leerink Partnrs analyst R. Ruiz anticipates that the medical equipment provider will post earnings per share of $1.32 for the quarter. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Leerink Partnrs also issued estimates for Lantheus’ Q3 2025 earnings at $1.51 EPS, Q4 2025 earnings at $1.57 EPS and FY2025 earnings at $5.77 EPS.

Several other equities analysts have also recently weighed in on LNTH. Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Trading Down 2.4 %

Shares of LNTH opened at $81.39 on Thursday. Lantheus has a 1 year low of $56.06 and a 1 year high of $126.89. The stock has a market cap of $5.66 billion, a P/E ratio of 13.54 and a beta of 0.44. The stock’s 50-day moving average price is $90.82 and its two-hundred day moving average price is $97.32.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Lantheus

Several institutional investors have recently added to or reduced their stakes in the company. Signaturefd LLC boosted its stake in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the period. State of New Jersey Common Pension Fund D lifted its position in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after acquiring an additional 115 shares during the period. Bleakley Financial Group LLC lifted its position in shares of Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after acquiring an additional 129 shares during the period. Avantax Advisory Services Inc. lifted its position in shares of Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock valued at $213,000 after acquiring an additional 132 shares during the period. Finally, Foundry Partners LLC lifted its position in shares of Lantheus by 4.5% during the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 133 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.